AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03029767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise .
Description: The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
Study NCT02710474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.
Study NCT03029767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed.
Study NCT03029767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise
Description: The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
Study NCT01886404 — intervention group
Intervention type: DRUG
Intervention: Efavirenz
Description: HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well.
Study NCT02270489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A + Adjuvant
Description: s.c. injection
Study NCT02270489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD03A + Adjuvant
Description: s.c. injection
Study NCT02270489 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant without active component
Description: s.c. injection
Study NCT02769013 — intervention group
Intervention type: OTHER
Intervention: Pre-treatment follow up
Description: No active intervention; medical support provided if needed
Study NCT02769013 — intervention group
Intervention type: OTHER
Intervention: S. haematobium treatment
Description: Praziquantel-treatment for S. haematobium positive volunteers
Study NCT02769013 — intervention group
Intervention type: OTHER
Intervention: Post treatment follow up
Description: No active intervention; medical support provided if needed.
Study NCT01194518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Program
Study NCT02280668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icing Therapy
Description: Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
Study NCT02280668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the eccentric muscle damage exercise
Study NCT02280668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the eccentric muscle damage exercise
Study NCT02769013 — intervention group
Intervention type: OTHER
Intervention: Olfactometer experiment
Description: No active intervention; medical support provided if needed.
Study NCT03395067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Lifestyle counseling coupled with psychotherapeutical intervention
Study NCT02482740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: letrozole 2.5 mg qd was given for 12 months or till disease progress
Study NCT02482740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: tamoxifen was given 20 mg qd for 12 months or till disease progress
Study NCT00703430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
Study NCT03800433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trental 400 MG Extended Release Oral Tablet
Description: oral tablets
Study NCT02880462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
Study NCT02880462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made of starch
Study NCT02882165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical review
Description: A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified
Study NCT02058641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
Study NCT02613091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Description: 4mg 2x day clemastine fumarate orally.
Study NCT03438513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Occupational Therapy Assessment
Description: The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
Study NCT03438513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological Assessment
Description: It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
Study NCT03438513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Problem Solving Therapy
Description: Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
Study NCT03438513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Speaking group
Description: Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
Study NCT03903536 — intervention group
Intervention type: PROCEDURE
Intervention: Thrombectomy
Description: A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
Study NCT03903536 — intervention group
Intervention type: PROCEDURE
Intervention: Hemorrhoidectomy
Description: A surgery to remove the hemorrhoid, including the blood vessels and clot.
Study NCT02899260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Exercise Ball
Description: A Peanut shaped exercise ball.
Study NCT01399840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Oral capsule with multiple dosage forms given once daily
Study NCT02734095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
Study NCT02939651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
Study NCT04752917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noise Cancelling headphones
Description: Use of headphones playing patients choice of music
Study NCT04611061 — intervention group
Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study NCT04611061 — intervention group
Intervention type: DRUG
Intervention: No one
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study NCT00289861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT00289861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03363165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VM202
Description: Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.
Study NCT03363165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.
Study NCT02623491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515
Description: Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
Study NCT02623491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT02608125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN1371
Study NCT02135549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SugarDown
Description: 4 or 8 gram dose in tablet form, before meals, daily for one week
Study NCT02135549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator
Study NCT01585168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
Study NCT01585168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
Study NCT01585168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identically appearing sugar pill, given orally
Study NCT01585168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing sugar pill, given orally
Study NCT01100294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FLUVAL P
Description: Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose.
Study NCT02335983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
Study NCT01137448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
Study NCT04889612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study NCT04889612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position
Description: In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study NCT02335983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.
Study NCT02590640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation, MagStim Rapid2
Description: This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain.
Study NCT02590640 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
Study NCT03146403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
Study NCT03146403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study NCT03146403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: Placebo
Study NCT04023136 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial hepatectomy by laparotomy on healthy or pathologic parenchyma.
Description: Preoperative flow and MRI + intraoperative measures of flow and pressures
Study NCT01060098 — intervention group
Intervention type: DRUG
Intervention: anti-TNF therapy (etanercept or adalimumab)
Description: Biological DMARD
Study NCT00906906 — intervention group
Intervention type: DEVICE
Intervention: Doppler probes
Description: Probes to be placed on CPB tubing to measure blood flow
Study NCT04632745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wrist Rehabilitation
Description: participants will undergo immobilization for the first 6 weeks of treatment
Study NCT02291445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)
Description: Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
Study NCT02291445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
Description: Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
Study NCT01024920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor
Study NCT01024920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: VEGF inhibitor
Study NCT02335983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
Study NCT00077922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: 40 micrograms/kg every other day (QOD) x 3 every 4 weeks
Study NCT04917250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/㎡，d1,4 ivdrip
Study NCT04917250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡, maximum dose less than 3750IU
Study NCT04917250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/㎡，d1-3 ivdrip
Study NCT04917250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg/d d1-4 ivdrip
Study NCT04606407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungFit™
Description: Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
Study NCT00626769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: aglycone genistein
Description: 2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
Study NCT00626769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: placebo
Description: 2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
Study NCT03560986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 100 mg
Description: 100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
Study NCT03560986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glass vials with matching placebo.
Study NCT05015322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: 5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
Study NCT05015322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: 5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
Study NCT05015322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
Study NCT01956058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy remedial
Description: brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
Study NCT02642848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HTO with microfracture
Description: High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix